Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03287245




Registration number
NCT03287245
Ethics application status
Date submitted
8/09/2017
Date registered
19/09/2017
Date last updated
8/12/2021

Titles & IDs
Public title
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Scientific title
A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Secondary ID [1] 0 0
2017-000861-58
Secondary ID [2] 0 0
NP39761
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Polycythemia Vera 0 0
Condition category
Condition code
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Idasanutlin

Experimental: Idasanutlin - Two cohorts of ruxolitinib-naïve and ruxolitinib-resitant or intolerant participants will be enrolled to receive idasanutlin once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years).


Treatment: Drugs: Idasanutlin
All participants will receive 150 milligrams (mg) idasanutlin orally, once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years). Intra-participant dose-escalation to 200 mg daily for 5 days may be permitted after Cycle 3 for those who demonstrate no hematocrit (Hct) control and/or for those with inadequately controlled leukocytosis and/or thrombocytosis in which the investigator judges that better control is important.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Ruxolitinib-Naïve Participants With Splenomegaly at Baseline Who Achieved Composite Response at Week 32
Timepoint [1] 0 0
Week 32
Primary outcome [2] 0 0
Percentage of Ruxolitinib-Naïve Participants Without Splenomegaly at Baseline Who Achieved Hematocrit (Hct) Control Without Phlebotomy at Week 32
Timepoint [2] 0 0
Week 32
Primary outcome [3] 0 0
Percentage of All Ruxolitinib-Naïve Participants (Irrespective of Spleen Size) Who Achieved Hct Control Without Phlebotomy at Week 32
Timepoint [3] 0 0
Week 32
Primary outcome [4] 0 0
Percentage of All Ruxolitinib-Resistant or Intolerant Participants Who Achieved Hct Control Without Phlebotomy at Week 32
Timepoint [4] 0 0
From Baseline to Week 32 (Cycle 8 Day 28)
Secondary outcome [1] 0 0
Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Who Achieved Complete Hematologic Response at Week 32
Timepoint [1] 0 0
Week 32 (Cycle 8 Day 28)
Secondary outcome [2] 0 0
Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Who Achieved Complete Hematologic Remission at Cycle 11 Day 28
Timepoint [2] 0 0
Cycle 11 Day 28
Secondary outcome [3] 0 0
Duration of Complete Hematologic Remission, With a Durable Responder Defined as a Participant in Remission at Week 32 and Cycle 11 Day 28
Timepoint [3] 0 0
Week 32 (Cycle 8 Day 28), Cycle 11 Day 28
Secondary outcome [4] 0 0
Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly at Baseline by Response Per Modified European Leukemia Net (ELN) Criteria
Timepoint [4] 0 0
Baseline, Day 28 of Cycles 3, 5, 8, 11, 12, 14, 17, 20 and Final visit (28 days after post-last dose)
Secondary outcome [5] 0 0
Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly at Baseline by Response Per Modified ELN Criteria
Timepoint [5] 0 0
Baseline, Day 28 of Cycles 3, 5, 8, 11, 12, 14, 17, 20 and Final visit (28 days after post-last dose)
Secondary outcome [6] 0 0
Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants (Irrespective of Spleen Size) by Response Per Modified ELN Criteria
Timepoint [6] 0 0
Baseline, Day 28 of Cycles 3, 5, 8, 11, 12, 14, 17, 20 and Final visit (28 days after post-last dose)
Secondary outcome [7] 0 0
Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks From Week 32
Timepoint [7] 0 0
From Week 32 (Cycle 8 Day 28) and at least 12 Weeks after until end of study (up to 2 years)
Secondary outcome [8] 0 0
Number of Participants With a Durable Response, in Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants With Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks From Week 32
Timepoint [8] 0 0
From Week 32 (Cycle 8 Day 28) and at least 12 weeks after until end of study (up to 2 years)
Secondary outcome [9] 0 0
Percentage of Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks From Week 32
Timepoint [9] 0 0
From Week 32 (Cycle 8 Day 28) and at least 12 Weeks after until end of study (up to 2 years)
Secondary outcome [10] 0 0
Number of Participants With a Durable Response, in Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants Without Splenomegaly at Baseline With Durable Response Lasting at Least 12 Weeks From Week 32
Timepoint [10] 0 0
From Week 32 (Cycle 8 Day 28) and at least 12 weeks after until end of study (up to 2 years)
Secondary outcome [11] 0 0
Percentage of All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants (Irrespective of Spleen Size) With Durable Response Lasting at Least 12 Weeks From Week 32
Timepoint [11] 0 0
From Week 32 (Cycle 8 Day 28) and at least 12 Weeks after until end of study (up to 2 years)
Secondary outcome [12] 0 0
Number of Participants With a Duration Response, in All Ruxolitinib-Naïve and Ruxolitinib-Resistant or Intolerant Participants (Irrespective of Spleen Size) With Durable Response Lasting at Least 12 Weeks From Week 32
Timepoint [12] 0 0
From Week 32 (Cycle 8 Day 28) and at least 12 weeks after until end of study (up to 2 years)
Secondary outcome [13] 0 0
Total Number of Participants With Adverse Events by Severity, Graded According to NCI CTCAE v4.0
Timepoint [13] 0 0
Baseline to end of study (up to 2 years)
Secondary outcome [14] 0 0
Percentage of Participants With Clinical Laboratory Abnormalities: Hematology Parameters.
Timepoint [14] 0 0
Baseline to end of study (up to 2 years)
Secondary outcome [15] 0 0
Percentage of Participants With Clinical Laboratory Abnormalities: Clinical Chemistry Parameters
Timepoint [15] 0 0
Baseline to end of study (up to 2 years)
Secondary outcome [16] 0 0
Percentage of Participants With Clinical Laboratory Abnormalities: Urinalysis Parameters
Timepoint [16] 0 0
Baseline to end of study (up to 2 years)
Secondary outcome [17] 0 0
Change From Baseline in Electrocardiogram Parameters: PQ(PR), QRS, QT, QTcB, QTcF, and RR Durations
Timepoint [17] 0 0
Baseline, Cycle 1 (Day 1, hours 4 and 6, Day 2 pre-dose and 24 Hour, Day 5 pre-dose, 4 and 6 Hour), Cycle 2 (Day 1 pre-dose only), Cycle 3 (Day 1 pre-dose, 4 and 6 Hour), Cycle 4 (Day 1 pre-dose and 4 Hour)
Secondary outcome [18] 0 0
Change From Baseline in Heart Rate, as Measured by Electrocardiogram
Timepoint [18] 0 0
Baseline, Cycle 1 (Day 1, hours 4 and 6, Day 2 pre-dose and 24 Hour, Day 5 pre-dose, 4 and 6 Hour), Cycle 2 (Day 1 pre-dose only), Cycle 3 (Day 1 pre-dose, 4 and 6 Hour), Cycle 4 (Day 1 pre-dose and 4 Hour)
Secondary outcome [19] 0 0
Change From Baseline in Oral Temperature
Timepoint [19] 0 0
Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Secondary outcome [20] 0 0
Change From Baseline in Pulse Rate
Timepoint [20] 0 0
Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Secondary outcome [21] 0 0
Change From Baseline in Respiratory Rate
Timepoint [21] 0 0
Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Secondary outcome [22] 0 0
Change From Baseline in Systolic Blood Pressure
Timepoint [22] 0 0
Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Secondary outcome [23] 0 0
Change From Baseline in Diastolic Blood Pressure
Timepoint [23] 0 0
Baseline, Cycle 1 (Days 15 and 22), Cycle 2 and 3 (Days 1 and 15), Each Cycle 4-23 (Day 1 only) and Final Visit
Secondary outcome [24] 0 0
Eastern Cooperative Oncology Group (ECOG) Performance Status Over Time
Timepoint [24] 0 0
Baseline
Secondary outcome [25] 0 0
Percentage of Participants With Concomitant Medications
Timepoint [25] 0 0
Overall Study Period
Secondary outcome [26] 0 0
Maximum Serum Concentration Observed (Cmax) of Idasanutlin
Timepoint [26] 0 0
Days 1, 2, and 5 of Cycles 1 and 4
Secondary outcome [27] 0 0
Trough Concentration (Ctrough) of Idasanutlin
Timepoint [27] 0 0
Days 1, 2, and 5 of Cycles 1 and 4
Secondary outcome [28] 0 0
Time of Maximum Concentration Observed (Tmax) of Idasanutlin
Timepoint [28] 0 0
Days 1, 2, and 5 of Cycles 1 and 4
Secondary outcome [29] 0 0
Clearance (CL) of Idasanutlin
Timepoint [29] 0 0
Days 1, 2, and 5 of Cycles 1 and 4
Secondary outcome [30] 0 0
Apparent Clearance (CL/F) of Idasanutlin
Timepoint [30] 0 0
Days 1, 2, and 5 of Cycles 1 and 4
Secondary outcome [31] 0 0
Volume or Apparent Volume of Distribution (Vdss/F) of Idasanutlin
Timepoint [31] 0 0
Days 1, 2, and 5 of Cycles 1 and 4
Secondary outcome [32] 0 0
Area Under the Concentration-Time Curve (AUC) of Idasanutlin
Timepoint [32] 0 0
Days 1, 2, and 5 of Cycles 1 and 4
Secondary outcome [33] 0 0
Half-life (t1/2) of Idasanutlin
Timepoint [33] 0 0
Days 1, 2, and 5 of Cycles 1 and 4
Secondary outcome [34] 0 0
Baseline and Mean Change From Baseline Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Over Time
Timepoint [34] 0 0
Baseline (Cycle 1 Day 1), Cycle 2 Day 1, Days 28 of Cycles 3, 5, 8 (Week 32), 11, 14, 17 ) Day 28, Cycle 5 Day 28, End of Cycle 8 (Week 32), and Final Visit
Secondary outcome [35] 0 0
Baseline and Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scores Over Time
Timepoint [35] 0 0
Baseline (Cycle 1 Day 1), Cycle 2 Day 1, Cycles 3, 5, 8, 11, 14, 17, 20 Day 28 and Final Visit
Secondary outcome [36] 0 0
Frequency Count of Participant Responses to the Patient Global Impression of Change (PGIC) Question Over Time
Timepoint [36] 0 0
Cycle 2 Day 1, Cycle 3 Day 28, Cycle 5 Day 28, End of Cycle 8 (Week 32), and every 3 cycles thereafter (1 cycle is 28 days) until end of study (up to 2 years)

Eligibility
Key inclusion criteria
* Documentation that the participant has met the revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia vera (PV)
* Hematocrit at screening and at initiation of idasanutlin greater than (>)40%
* Phlebotomy-dependent participants with splenomegaly by magnetic resonance imaging (MRI) or computerized tomography (CT) imaging (greater than or equal to [=]450 cubic centimeters [cm^3]) or without splenomegaly (less than [<]450 cm^3 or prior splenectomy)
* Resistance to/intolerance to hydroxyurea according to modified European Leukemia Net (ELN) criteria
* For participants in the ruxolitinib intolerant or resistant group, in addition to previous hydroxyurea intolerance/resistance: Therapy-resistant PV after at least 6 months of treatment with ruxolitinib, as defined in the protocol; Ruxolitinib intolerance, as defined in the protocol; and Documentation of adverse events likely caused by ruxolitinib (assessment of attending physician) and that are of a severity that preclude further treatment with ruxolitinib (as per judgment of the attending physician and the patient)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
* Participants must be willing to submit the blood sampling and bone marrow sampling for the pharmacokinetic (PK) and pharmacodynamic analyses and exploratory biomarkers
* Adequate hepatic and renal function
* Ability and willingness to comply with the study protocol procedures, including clinical outcome assessment measures
* For women of childbearing potential: agreement to use contraceptive methods that result in a failure rate of less than (<)1% per year during the treatment period and for at least 6 weeks after the last dose of idasanutlin
* For men: Agreement to use contraceptive measures, and agreement to refrain from donating sperm during the treatment period and for at least 90 days after the last dose of idasanutlin
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Meets the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
* Blast phase disease (>20% blasts in the marrow or peripheral blood)
* Clinically-significant thrombosis within 3 months of screening
* Participants who must receive CYP2C8 inhibitors, substrates and inducers, strong CYP3A4 inducers, or OATP1B1/3 substrates while on study. These must be discontinued 7 days (inhibitors and substrates) or 14 days (inducers) prior to start of study medication
* Previously treated with murine double minute 2 (MDM2) antagonist therapies or receiving interferon-alpha, anagrelide, or ruxolitinib within 28 days or 5 half-lives (whichever is shorter), or hydroxyurea within 1 day, or receiving any other cytoreductive or investigational agents within 28 days or 5 half-lives (whichever is shorter) of initial dose. Aspirin is permitted per treatment guidelines for PV unless medically contraindicated
* Patients with evidence of electrolyte imbalance such as hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia of Grade >1 intensity, as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, prior to dosing on Cycle 1 Day 1. Treatment for correction of electrolyte imbalances is permitted to meet eligibility
* Neutrophil count <1.5 × 10^9/Liter (L) prior to dosing on Cycle 1 Day 1
* Platelet count less than or equal to (=)150 × 10^9/L prior to dosing on Cycle 1 Day 1
* Women who are pregnant or breastfeeding
* Ongoing serious non-healing wound, ulcer, or bone fracture
* History of major organ transplant
* Uncontrolled intercurrent illness including, but not limited to hepatitis, concurrent malignancy that could affect compliance with the protocol or interpretation of results, hepatitis A, B, and C, human immunodeficiency virus (HIV)-positive, ongoing or active infection, clinically significant cardiac disease (New York Heart Association Class III or IV), symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Concurrent malignancy exceptions include: Curatively treated carcinoma in situ of the cervix, good-prognosis ductal carcinoma in situ of the breast, basal- or squamous-cell skin cancer, Stage I melanoma, or low-grade, early-stage localized prostate cancer. Any previously treated early-stage non-hematological malignancy that has been in remission for at least 2 years is also permitted.
* Patients with active gastrointestinal conditions (Crohn's disease, ulcerative colitis, diverticulosis associated colitis, and Behçet's disease)
* Clinically significant toxicity (other than alopecia) from prior therapy that has not resolved to Grade =1 (according to the NCI CTCAE, v4.0) prior to Cycle 1 Day 1
* Cardiovascular disease, such as: uncontrolled arterial hypertension; symptomatic congestive heart failure or ejection fraction below 55% at screening, or left ventricular hypertrophy; any significant structural abnormality of the heart at screening echocardiogram; unstable angina pectoris; presence or history of any type of supraventricular and ventricular arrhythmias, including lone atrial fibrillation or flutter

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/02/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
3/03/2020
Sample size
Target
Accrual to date
Final
27
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 0 0
Royal Adelaide Hospital; Haematology Clinical Trials - Adelaide
Recruitment hospital [2] 0 0
Peter MacCallum Cancer Centre; Department of Haematology - Melbourne
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3002 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Kansas
Country [3] 0 0
United States of America
State/province [3] 0 0
New York
Country [4] 0 0
United States of America
State/province [4] 0 0
Ohio
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas
Country [6] 0 0
Canada
State/province [6] 0 0
Ontario
Country [7] 0 0
Italy
State/province [7] 0 0
Lombardia
Country [8] 0 0
Italy
State/province [8] 0 0
Toscana

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT03287245